Navigation Links
Weikang Bio-Technology Announces Filing for NASDAQ Listing
Date:6/22/2010

HARBIN, China, June 22 /PRNewswire-Asia-FirstCall/ -- Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT) ("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced that the Company had filed an application to list its common stock on the NASDAQ Capital Market.

"This is an important milestone for Weikang as we continue to expand our business and broaden our market penetration," commented Mr. Yin Wang, Chairman and CEO of Weikang Bio-Technology Group. "NASDAQ is a prestigious senior exchange that is well suited for rapidly growing companies such as Weikang that meets its stringent listing requirements. If approved, the listing can help to broaden the Company's shareholder base, provide greater trading liquidity and raise the Company's profile in the investment community."

Weikang believes it satisfies the majority of the listing qualifications associated with this application. The application is subject to review by NASDAQ's Listing Qualifications Department for compliance with all NASDAQ Capital Market requirements. The Company's common stock will continue to trade on the OTC Bulletin Board under its current symbol, WKBT, until the Company is notified of its acceptance.

About Weikang Bio-Technology Group Co., Inc.

Weikang Bio-Technology Group Co., Inc. is principally engaged in developing, manufacturing and distributing Traditional Chinese Medicine (TCM), and health and nutritional supplements in China, in compliance with requisite Chinese licenses and approvals. The Company is also expanding its business scope to develop, manufacture and distribute Chinese herbal extract products and GMP certified western prescription and OTC pharmaceuticals through its acquisition of Tianfang. For more information, please visit http://www.weikangbio.com .

Safe Harbor Statement

This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

    For more information, please contact:

    Company contact:

     Ren Hu, VP of Finance
     Weikang Bio-Technology Group Co., Inc.
     US Tel:     +1-201-887-0415
     China cell: +86-137-1872-8163
     Email:      arenhu@gmail.com

    Investors Relation contact:

     John Marco, Partner, Elite IR
     Tel:   +1-310-819-2948
     Email: John.marco@elite-ir.com

     Leslie J. Richardson, Partner, Elite IR
     Tel:   +852-3183-0283
     Email: Leslie.richardson@elite-ir.com


'/>"/>
SOURCE Weikang Bio-Technology Group Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Weikang Bio-Technology Reports First Quarter 2010 Financial Results
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... Bio-Ess Laboratories, LLC Chief Science Officer, Dr. Adam Elhofy , will ... Cell-Ess® Universal Titer Boost at the 9 th annual ... 21-25.  The Bioprocessing Summit convenes more than 1,000 international bioprocess professionals to ... ... Cell-Ess is the ...
(Date:8/15/2017)... FLINT, Mich. , Aug. 15, 2017 ... antidote naloxone to Michigan residents. ... Diplomat,s Flint retail pharmacy, G-3320 ... Naloxone, approved by the Food and Drug Administration, is ... drugs—including extreme drowsiness, slowed breathing, and loss of consciousness. ...
(Date:8/15/2017)... , Aug. 15, 2017 AccuGenomics, Inc., ... , today announced that the company has provided ... University of North Carolina at Chapel Hill and to ... designed to characterize and quantify HIV reservoir and viral ... pharmacological intervention. The HIV Cure Center is a joint ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... August 18, 2017 , ... As an industry leader, Eppendorf ... they will present the line of epMotion automated liquid handling system. This automated ... automate everyday pipetting tasks. , Ideal for scientists and lab technicians with no ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... planning services to communities in east Texas, is launching a regional charity effort ... , Founded in 1991, the Pediatric Brain Tumor Foundation (PBTF) has raised nearly ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Golseth Agency, a Texas based ... area, is spearheading a regional charity campaign organized to provide support to Christina Upchurch ... of this year, Christina and her children returned from out of town to find ...
(Date:8/18/2017)... ... ... Alcovit, a lime-flavored beverage that rids the body of toxins linked to alcohol ... through Jet.com. , After 25 years of development, the company released its highly ... detox the body thereby avoiding alcohol-induced hangovers. Whether you’re having fun with friends or ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... “Dangerous Inheritance”: ... published author, Diane Winters. Diane is from Southwest Nebraska where she was raised ... friends and family. The story is fictional, but the friendships and mantra of ...
Breaking Medicine News(10 mins):